Fig. 1
From: Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
Drug candidates identified through high throughput drug screening in ACC: A 10 × 10 combination matrix screening data demonstrating the drug synergy between OTS167 and RGB-286638. B HSA synergy of OTS167 and RGB-286638 drugs. C Dose–response curve comparing OTS167 (left panel) and RGB-286638 (right panel) with the current standard of care chemotherapy: cisplatin, doxorubicin, etoposide, mitotane, and streptozocin in NCI-H295R and SW13 cells